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CLINICAL STUDY OF RETROPERITONEAL LYMPH NODE DISSECTION 
FOR PATIENTS WITH ADVANCED GERM CELL TUMORS 
Kikuo OKAMURA， Hiroshi YUBA， Tatsuya NISHIMURA， Kazuo MIZUTANI， 
Munehisa T AKASHI， Momokazu GOTOHラ Yoshinari ONO and Shinichi OHSHIMA 
From the Dψαrtment 01 Urology， NagりaUniversity School 01 Medicine 
We performed retroperitoneal lymph node dissection (RPLND) on 14 patients (IIA: 1ラ IIB:4ラ
IIIA: 3ラIIIB2:2うIIIC:4) with testicular and one with retroperitoneal germ cel tumor at the Nagoya 
University Hospital between 1986 and 1997. According to the international germ cel consensus 
classification， 4 patients were classified as“good-prognosis勺threeas “intermediate-prognosis" and 
eight as“poor-prognosis". RPLND was performed on 12 patients with the tumor marker levels 
normalized preoperatively and on three without the marker normalization. The mean surgical time 
was 510 (195ーし125)minutes and the mean bleeding volume was 3ラ806(100-12ラ598)g. The surgical 
time and bleeding volume were correlated with the size of the tumor in the body axis. Intraoperative 
complications occurred in 5 (33%) out of 15 patients : injury of renal artery (2)ラrenalvein (1)ラureter
(1) and common iliac artery (2). Postoperative complications occurred in 2 patients : ileus (2) and 
lower extremi ty edema resulting from resection of the inferior vena cava (1) and wound dehiscence (1). 
Of the 8 patients whose completely resected retroperitoneal tumors were necrosis/長brosisor teratoma 
(psCR)， 6 achieved survival with no evidence of disease (NED). Among 4 patientsラwhosetumor was 
not completely resected but pathologically diagnosed as necrosis/fibrosis or teratoma (pCR)， NED 
without recurrence was achieved in 2 and also in one with resection of relapsed teratoma 2.5 years after 
RPLND. All three patients with cancer tissues pathologically retained in the resected tumors (sCR or 
psIR)， consequently died of the disease. In six patients with relapse， the initial sign was elevation of 
the tumor marker levelsうwhichwas noted more than 30 days postoperatively in 2 patients with psCR 
and 7 to 15 days in 4 patients without psCR. We believe that RPLND is needed to examine the 
pathology and to predict the prognosis of the poor-risk patients with NSGCT. Careful dissection of 
vessels is needed to reduce vascular complications. 
(Acta Urol. Jpn. 45: 95-101ラ 1999)




























96 泌尿紀要 45巻 2 1999年
Table 1. Patientsう characteristics
AU proI1i z pathology AFP bHCG Metastic 
Pre幽 Post-che- Post-
RPLND motherapy chemotherapeay i 
No Age IGCCC dtrnary(n/ml)(n/ml)LDH料 0伽自由 chemo- marker- retroperitone stage tumor' ~ng/ml) ~ng/ml) than RPLN 
therapy norη叫 ization mass (cm) 
1 32 IIA good S 3 0.11 1.4 PVB (3) yes 3.6 X 2.6 X 2.0 
2 17 IIIC poor E， YS 20，000 0.5 6.2 boneラlung PVB((23) )ヲ yes 7X 5X 6 
VIP 
3 20 IIIB2 poor YSフimT 65，000 2.3 4 med，lung， VAB6 (4)フ yes 4X 5X 12
cerv VIP (2 
4 36 IIB poor YS， S 1，622 0.2 1.1 VAB6 (4)フ
VIP (2 
yes 3.2X2.2X9.5 
5 31 IIIB2 good E，mT，C 3 646 lung VAB6/EP 
(4)， EP (3) 
yes 3X 2X1.6 
6 45 IIIA poor S， YS 14，877 21.5* 1.5 med VIP (4) yes 3X 5X 16 
7 35 IIIC poor YSヲC 48ラ008 300 18.8 lungラliver VPOIP M(B6)， (2) yes 3X 4X 19 
8 36 IIB intermed S， YS 1ラ278 1.8 2.6 BEP (3) yes 2X 2x 3 
9 33 IIB good SぅmT 4 5.2 0.8 BEP((33) )う yes 3X 3X 3 
VIP 
10 31 intermed 3 950 8.7 lung BEP((33) )う no 4.5X5.5X7.0 
VIP 
1 36 IIIA intermed imT， E 724 13 3.2 medうcerv BEP((33) )ヲ no 9X 7X16 
VIP 
12 38 IIIA poor S， E， imT 16.8 6.1 10.3 med BEP (3) yes 7X 3X17 
13 25 IIIC poor S 43 2ヲ250 2.2 medラlung， BEPC(12E)C ララ no 5X3.2X16 
liver， spleen VIP 
HD-CEC (1) 
14 21 IIIC poor E， mT， C 4ラ300 450 2.9liven BEPV((3iP ) ラ yes 5X 3X19 
adrenalうcervVIP 
HD-VP16 
15 32 IIB good EうSヲmT 21 0.5>* BEP (2) yes 13XlOX16 
IGCCC: lnternational germ cel consensus criteriaうintermed:intermediate， S:seminoma， E: embryonal carcinomaう YS
yolk sac tumor， im or mT: immature or mature teratoma， C: choriocaricinoma， *. IU/Iラ**:devided by upper limitぅ
cerv: cervical nodes， med: mediastinumう PVB:CDDP， VP-16， BLM， VIP: VP-16， IFXラ CDDPう VAB6:VLBラ ActDう
BLMラ CDDP，CTXラ EP:VP-16， CDDP， POMB: CDDPう VCRう MTXラ BLMラ BEP:BLM， VP-16ラ CDDPラ HD-CEC














good -prognosis症例 4例， intermediate-prognosis症
例 3例， poor-prognosis症例 8例であった11)
全例，化学療法後に後腹膜リンパ節郭清術が施行さ
れた.導入化学療法後，後腹膜リンパ節郭清術を施行
した 5f7U (PVB3): 1仔U，BEp3): 3 f7U， VlpI2): 1 
例)では， すべての症{伊例予列tで
ていた.救済化学療法後，後腹膜リンパ節郭清術を施
行した 7例 (VIP:4例， EpI3): 1例， POMB2) : 1 












のが6例 5cm以上 10cm未満のものが8例， 10
cm以上のものが l例であった.体軸上では病変の及
ぶ範囲が 5cm未満のもの 4例， 5cm以上 10cm未












学的に癌細胞を認めた場合を sCR(surgical CR) ， 
全切除ができ病理学的にも壊死または線維性組織ある
いは奇形腫であった場合を psCR，完全切除もできず








手術時間は， 195分から 1，125分まで平均51O:!:259 
分，出血量は 100gから 12，598gまで平均 3.806土




































Results of the retroperitoneal lymph nodes dissection 
N Operative Bleeding 
















N eulilemmoma NED 
N/F DOD (bone) 
imT NED 

















































A WD (lung， RPLN) 
NED 




























































of multiple metastases removed after RPLND， IVC: inferior vena cavaラ RV:renal vein， RA: renal arteryぅCIA
common iliac arteryぅ p/s:pathological/surgicalラ CR:complete responseラ IR:incomplete responseぅ m/im T: mature/ 
Immature teratoma， N/F: necrosis/fibrosisう NED:no evidence of disease， DOD: dead of disease， A WD :alive with dis開
none 





と5cm以上 10cm未満の群(3例)， 10 cm以上の
群(8例)に分けると，それぞれの群の手術時間は
290土96分， 403土81分， 660土265分であり，出血量は













術後合併症では，イレウスが2例 (No.10， 15) 
に，下大静脈切除による著明な下肢の浮腫が l例






2)， 4例で pCR(壊死/線維組織:3，奇形臆:1 ) ，
I例で sCR(癌)が得られた.マーカ一正常化以前
にやむなく後日昼膜リンノf節郭清4荷を行った 3例のう
ち例が psCR(壊死/線維組織)， 2例が psIRで
あった.最終的に， psCR 8例中 6例， pCR 4例中 3
f列で NEDを得た. psCR 1例と pCR1例， sCR 1 





(No. 1， 5， 6， 8， 9， 12， 15)中， 5例に痘ちに後腹
膜リンパ節郭清術を施行した.後腹膜リンパ節の病理






















上 10cm未満の 3例では psCR2例， pCRが l例で
あり， psCRの l例のみで NEDを達成した. lOcm 
以上の8例では psCR2例， pCR 3例， sCR 1例，




















































































































































































































pCR， sCRの症例では 7-15日自， psCR症例では
32日と90日であった.
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